Thelansis’s “Moderate to Severe Rheumatoid Arthritis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Moderate to severe rheumatoid arthritis is a chronic autoimmune disorder in which persistent inflammation of the synovial lining leads to progressive joint damage, pain, stiffness, swelling, and functional disability, often accompanied by systemic complications such as cardiovascular disease, lung involvement, and fatigue. At these stages, patients experience significant impairment in daily activities, with disease activity measured through composite scores and biomarkers like rheumatoid factor and anti‑CCP antibodies. Management requires early, aggressive therapy with disease‑modifying antirheumatic drugs (DMARDs) such as methotrexate, often combined with biologic or targeted synthetic agents including TNF inhibitors, IL‑6 receptor blockers, or JAK inhibitors, while corticosteroids and NSAIDs provide symptomatic relief. Despite advances, many patients continue to face flares and progression, underscoring the need for personalized treatment strategies, vigilant monitoring, and innovation in targeted therapies to preserve joint function, reduce systemic risks, and improve long‑term outcomes.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Moderate to Severe Rheumatoid Arthritis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report
Our team will get in touch with you shortly about the Moderate to Severe Rheumatoid Arthritis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report.